

BIO-GENE TECHNOLOGY INVESTOR BRIEFING

Bio-Gene Technology Limited's (ASX: BGT) CEO Richard Jagger will lead an investor briefing webinar at 11am AEDT Thursday, 28 October 2021.

The webinar will cover major news this week and upcoming program:

- Recent commercial agreements for consumer and public health applications
- Other business updates
- · Program pipeline going forward

To attend the presentation, please register using the following link: https://zoom.us/webinar/register/WN_9mqXKZL7ThqNaTDU3SWE6Q

The presentation slides will be available on the company website shortly before the event is scheduled to commence.

Approved for release by the Chairman of the Board.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger Roger McPherson

Chief Executive Officer CFO & Company Secretary

P: 03 9068 1062 P: 03 9068 1062

E: <u>bgt.info@bio-gene.com.au</u> E: <u>bgt.info@bio-gene.com.au</u>

IR/Media

Rudi Michelson

Monsoon Communications

P: 03 9620 3333

E: rudim@monsoon.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions, working with industry leaders across key market segments.